On 23 October 2026, Administrative Order No. 465/2026/1 was published, which aims to regulate the provision, free of charge, of medicines and medical devices to participants in clinical trials following the conclusion of their participation in such trials, in accordance with the provisions of Article 14 of Law No. 9/2026 of 6 March. The legislation aims to set out the terms of this provision; amongst other things, it stipulates that the obligation rests with the sponsor, who must ensure that the medicine is supplied free of charge for as long as the investigator considers it essential for the continuation of treatment and there are no comparable therapeutic alternatives.
